Encouragingly, the MMT‐driven CAF formation (α‐SMA) as well as LLC‐tumor growth in the Smad3‐WT BMDM‐received mice was significantly reduced by the macrophage‐specific silencing of Smad3 (Smad3‐KO BMDM) (Figure 6C,D), suggesting Smad3 as a potential therapeutic target for eliminating MMT‐driven CAF formation. This evidence concerns the gene SMAD3 and neoplasm.